Implementation of a dose adjustment program for patients with impaired renal function;Implantación de un programa de ajuste posológico en pacientes con función renal disminuida

Atencion Farmaceutica

Volumn 9, Issue 2, 2007, Pages 102-106

  Fernandez Diaz E ^a   Goikolea Ugarte, F J ^a   Domingo Echaburu, S ^a   Dominguez Menendez J A ^a   Balzola Regout, B ^a   Yurrebaso Ibarretxe, Ma J ^a  

^a HOSPITAL DE BASURTO   (Spain)

Author keywords

Dose adjustment; Pharmaceutical intervention; Renal failure

Indexed keywords

ACETAZOLAMIDE; ACICLOVIR; ALLOPURINOL; AMIKACIN; AMILORIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B; AMPICILLIN; ANTIDIABETIC AGENT; BACLOFEN; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFEPIME; CIPROFLOXACIN; CLARITHROMYCIN; COLCHICINE; CREATININE; ENOXAPARIN; FLUOXETINE; GLIBENCLAMIDE; INDOMETACIN; METFORMIN; METOCLOPRAMIDE; PETHIDINE; PHENYTOIN; QUINOLONE DERIVATIVE; RANITIDINE; SULPIRIDE; UNINDEXED DRUG; VENLAFAXINE;

AGED; CARDIOLOGY; COMPUTER PROGRAM; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; HUMAN; INTERNAL MEDICINE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICAL ORDER; NEPHROLOGY; REVIEW;

EID: 34547103509     PISSN: 11397357     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drugs reactions in hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
2. Martin-Facklam M, Rengelshausen J, Tayrouz Y, et al. Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol 2005; 60: 807-11.
3. Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by inmediate concurrent feedback. J Gen Intern Med 2001; 16: 369-75.
4. Bates DW, Spell N, Cullen DJ, et al. The cost of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277: 307-11.
5. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1997; 277: 301-6.
6. Fernández E, Goikolea J, Aguirrezabal A, Domingo S, Álvarez M, Vilella ML. Programa de ajuste posologico en pacientes con función renal disminuida. Farm Hosp 2004; 28:40
7. Fernández E, Goikolea J, Domíngo S, Domínguez J, Elguezabal I, Yurrebaso MJ. Implantación de un programa de ajuste posológico en pacientes con función renal disminuida. Farm Hosp 2005; 29: 35.
8. rd ed. Philadelphia: American College of Physicians; 1994.
9. th ed. Antimicrobial Therapy, Inc., Hyde Park, Vt. (USA). 2004.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
11. Schneider V, Henschel V, Tadjalli-Mehr K, Mansmann U, Haefeli WE. Impact of serum creatinine measurement error on dose adjustment in renal failure. Clin Pharmacol Ther 2003; 74: 458-67.
12. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13: 2140-4.
13. Hu KT, Matayoshi A, Stevenson FT. Calculation of the estimated creatinine clearance in avoiding drug dosing errors in the older patient. Am J Med Sci 2001; 322: 133-6.
14. Gea Rodríguez E, Manso Mardones P, Barral Viñals N, Indo Berges O, Bofarull Gallofré J. Programa intensivo de seguimiento y ajuste posológico en pacientes con insuficiencia renal. Aten Farm 2003; 5: 200-9.
15. Elizondo G, Buil P, Díez V, Garjón J, Guisasola L, Martínez C et al. Utilización de la concentración de la creatinina sérica para la dosificación de medicamentos en insuficiencia renal. Farm Clin 1994; 11: 484-9.